ADOPTIVE CELL THERAPY

In 2019, an infographic on adoptive cell therapy was published. This is an updated presentation of the happenings in the field in the past five years (from 1/1/19)






What is ADOPTIVE Cell Therapy?


Currently, Trialtrove classifies adoptive cell therapy (ACT) into three types with their own mechanism of action, namely ACT with tumor-infiltrating lymphocytes (TIL), ACT using T cell receptor (TCR) gene therapy, and ACT with chimeric antigen receptor modified T cells (CAR-T).

Trials initiated in past 5 years

Research reaches new high



Industry vs. non-industry sponsored trials and TOP 3 companies developing adoptive cell therapy




Geographic distribution

China and United States continue to hold the leading position in the ACT pipeline



Top 5 diseases per therapy



researchers the most for hematological cancers; non-Hodgkin's lymphoma tops the list. T-cell receptors and TIL therapies are being mostly studied in solid tumors. 4 CART drugs in the United States and 3 CART therapies in China granted approval for hematological cancers since 2019

Relmacabtagene autoleucel Lisocabtagene maraleucel

Idecabtagene vicleucel Ciltacabtagene autoleucel Brexucabtagene autoleucel

In United States

Equecabtagene autoleucel

In China



To learn more, visit Citeline.com or email clientservices@citeline.com

LEARN MORE